Standalone audited financial reults of the Company for the quarter and financial year ended on 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jenburkt Pharmaceuticals reported standalone revenue from operations of ₹1,687.41 Cr for FY26, up 11.2% from ₹1,516.92 Cr in FY25. PAT grew to ₹347.36 Cr vs ₹320.61 Cr, an 8.3% YoY increase, with Q4 PAT at ₹108.50 Cr up 27.1% YoY. EPS stood at ₹78.71 per share (FY26). An exceptional charge of ₹39.51 Cr was recorded due to the Government of India's Revised Labour Codes (November 2025), which increased gratuity and leave liabilities by ₹3,395.11 L due to past service costs. Profit before tax (before exceptional items) was ₹504.70 Cr, up 14.9% YoY. The Board approved a dividend of ₹220.70 per share (207%) for FY26. The auditors (D.R. Mehta & Associates) issued an unmodified opinion with no going concern issues.
Solid revenue and profit growth with an unmodified audit opinion — the one-time labour code charge compresses FY26 net profit but is non-recurring. The generous dividend payout signals management confidence. No material concerns for shareholders.